{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:44:14Z","timestamp":1793105054681,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Jeffrey Michael Gorvetzian Endowment for Biomedical Excellence"},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHS-N272201400053C"],"award-info":[{"award-number":["HHS-N272201400053C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHS-N272200800039C"],"award-info":[{"award-number":["HHS-N272200800039C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01-AI061142"],"award-info":[{"award-number":["U01-AI061142"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"DOI":"10.13039\/100015283","name":"Bloomberg Philanthropies","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015283","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pre-erythrocytic malaria vaccines that induce high-titer, durable antibody responses can potentially provide protection from infection. Here, we engineered a virus-like particle (VLP)-based vaccine targeting a recently described vulnerable epitope at the N-terminus of the central repeat region of the\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    circumsporozoite protein that is recognized by the potently inhibitory monoclonal antibody L9 and show that immunization with L9 VLPs induces strong antibody responses that provide protection from blood-stage malaria in a mouse infection model.\n                  <\/jats:p>","DOI":"10.1038\/s41541-022-00457-1","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T06:06:27Z","timestamp":1646719587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model"],"prefix":"10.1038","volume":"7","author":[{"given":"Lucie","family":"Jel\u00ednkov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevel","family":"Flores-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2246-3319","authenticated-orcid":false,"given":"Sarah","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce T.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-5245","authenticated-orcid":false,"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1414-6196","authenticated-orcid":false,"given":"Fidel","family":"Zavala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5712-4739","authenticated-orcid":false,"given":"Bryce","family":"Chackerian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,8]]},"reference":[{"key":"457_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1056\/NEJM199701093360202","volume":"336","author":"JA Stoute","year":"1997","unstructured":"Stoute, J. A. et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S malaria vaccine evaluation group. N. Engl. J. Med. 336, 86\u201391 (1997).","journal-title":"N. Engl. J. Med."},{"key":"457_CR2","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","volume":"374","author":"A Olotu","year":"2016","unstructured":"Olotu, A. et al. Seven-year efficacy of RTS,S\/AS01 malaria vaccine among Young African Children. N. Engl. J. Med. 374, 2519\u20132529 (2016).","journal-title":"N. Engl. J. Med."},{"key":"457_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0969-8","volume":"14","author":"MA Penny","year":"2015","unstructured":"Penny, M. A., Pemberton-Ross, P. & Smith, T. A. The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease. Malar. J. 14, 437 (2015).","journal-title":"Malar. J."},{"key":"457_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"SCTP Rts","year":"2015","unstructured":"Rts, S. C. T. P. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","journal-title":"Lancet"},{"key":"457_CR5","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.4512","volume":"24","author":"NK Kisalu","year":"2018","unstructured":"Kisalu, N. K. et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat. Med. 24, 408\u2013416 (2018).","journal-title":"Nat. Med."},{"key":"457_CR6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.immuni.2020.08.014","volume":"53","author":"LT Wang","year":"2020","unstructured":"Wang, L. T. et al. A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver. Immunity 53, 733\u2013744.e738 (2020).","journal-title":"Immunity"},{"key":"457_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00302-x","volume":"6","author":"E Atcheson","year":"2021","unstructured":"Atcheson, E., Hill, A. V. S. & Reyes-Sandoval, A. A VLP for validation of the Plasmodium falciparum circumsporozoite protein junctional epitope for vaccine development. NPJ Vaccines 6, 46 (2021).","journal-title":"NPJ Vaccines"},{"key":"457_CR8","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/vaccines9030272","volume":"9","author":"JR Francica","year":"2021","unstructured":"Francica, J. R. et al. Design of alphavirus virus-like particles presenting circumsporozoite junctional epitopes that elicit protection against malaria. Vaccines 9, 272 (2021).","journal-title":"Vaccines"},{"key":"457_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nm.4513","volume":"24","author":"J Tan","year":"2018","unstructured":"Tan, J. et al. A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nat. Med. 24, 401\u2013407 (2018).","journal-title":"Nat. Med."},{"key":"457_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00274-4","volume":"6","author":"L Jelinkova","year":"2021","unstructured":"Jelinkova, L. et al. An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein. NPJ Vaccines 6, 13 (2021).","journal-title":"NPJ Vaccines"},{"key":"457_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/v12010074","volume":"12","author":"B Chackerian","year":"2020","unstructured":"Chackerian, B. & Peabody, D. S. Factors that govern the induction of long-lived antibody responses. Viruses 12, 74 (2020).","journal-title":"Viruses"},{"key":"457_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-3055-9","volume":"18","author":"Y Flores-Garcia","year":"2019","unstructured":"Flores-Garcia, Y. et al. Optimization of an in vivo model to study immunity to Plasmodium falciparum pre-erythrocytic stages. Malar. J. 18, 426 (2019).","journal-title":"Malar. J."},{"key":"457_CR13","doi-asserted-by":"publisher","first-page":"e1008373","DOI":"10.1371\/journal.ppat.1008373","volume":"16","author":"D Oyen","year":"2020","unstructured":"Oyen, D. et al. Structure and mechanism of monoclonal antibody binding to the junctional epitope of Plasmodium falciparum circumsporozoite protein. PLoS Pathog. 16, e1008373 (2020).","journal-title":"PLoS Pathog."},{"key":"457_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00272-6","volume":"6","author":"JM Calvo-Calle","year":"2021","unstructured":"Calvo-Calle, J. M., Mitchell, R., Altszuler, R., Othoro, C. & Nardin, E. Identification of a neutralizing epitope within minor repeat region of Plasmodium falciparum CS protein. NPJ Vaccines 6, 10 (2021).","journal-title":"NPJ Vaccines"},{"key":"457_CR15","first-page":"38","volume":"15","author":"LT Wang","year":"2022","unstructured":"Wang, L. T. et al. The light chain of the L9 antibody is critical for binding circumsporozoite protein minor repeats and preventing malaria. Cell Rep. 15, 38 (2022).","journal-title":"Cell Rep"},{"key":"457_CR16","doi-asserted-by":"publisher","first-page":"e107764","DOI":"10.1371\/journal.pone.0107764","volume":"9","author":"AR Noe","year":"2014","unstructured":"Noe, A. R. et al. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate. PLoS ONE 9, e107764 (2014).","journal-title":"PLoS ONE"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00457-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00457-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00457-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T09:35:54Z","timestamp":1669282554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00457-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,8]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["457"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00457-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.11.10.465032","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,8]]},"assertion":[{"value":"30 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.C. has equity in FL72, a company that does not have financial interest in malaria vaccines. N.P. is affiliated with Vaxine Pty Ltd, a company having a financial interest in Advax adjuvants. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}